KP-701 / Jasper Therapeutics - LARVOL DELTA

Corporate Updates for Second Quarter 2026 and Recent Weeks (GlobeNewswire) - "KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026. Based on previous, positive results in treatment-naïve PNH, the combined company is also planning for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and plans to announce next steps for development in PNH in the first half of 2027...Based on positive, long-term data generated in SCID, the combined company is progressing its efforts towards a pre-BLA meeting with the FDA and expects to announce next steps in the first quarter of 2027....The combined company expects to file a clinical trial application (CTA) and/or an investigational new drug (IND) for Phase 1 evaluation in the first quarter of 2027."

IND • New P1 trial • New P2 trial • P2 data • Glomerulonephritis • Immunology • Paroxysmal Nocturnal Hemoglobinuria • Systemic Lupus Erythematosus • Transplantation

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals (GlobeNewswire) - "The Combined Company will focus on advancing a consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven disorders, including KP-104, a potential best-in-class dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)...an anti-KIT antibody with broad therapeutic utility across multiple transplant and immunologic indications, and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders....Based on previous, positive data in treatment-naïve PNH, the Combined Company is planning for an end-of-Phase 2 meeting with the FDA and plans to announce next steps in the first half of 2027....In the first quarter of 2027, the Combined Company expects to file a clinical trial application (CTA) or an investigational new drug (IND) for Phase 1 testing and plans to report first in human data in the third quarter of 2027."

FDA event • IND • M&A • Paroxysmal Nocturnal Hemoglobinuria • Systemic Lupus Erythematosus